Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Journal of Cardiovascular Pharmacology|September 11, 2015
Pharmacogenetic-guided Warfarin Dosing Algorithm in African-AmericansSameh Alzubiedi, Mohammad I SalehAmerican Journal of Therapeutics|October 14, 2015
Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus InfectionSameh Alzubiedi, Mohammad I SalehMolecular Diagnosis & Therapy|February 28, 2014
Dosage individualization of warfarin using artificial neural networksMohammad I Saleh, Sameh AlzubiediEuropean Journal of Drug Metabolism and Pharmacokinetics|June 28, 2018
Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C PatientsMohammad I Saleh, Suhad Bani Melhim, Hanguin M Al-Ramadhani, et al.Clinical Pharmacokinetics|April 12, 2017
A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C PatientsMohammad I SalehAmerican Journal of Therapeutics|April 2, 2015
Clinical Predictors Associated With Warfarin SensitivityMohammad I SalehMolecular Biology Reports|February 28, 2012
UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian populationNancy Hakooz, Sameh Alzubiedi, Al-Motassem Yousef, et al.International Journal of Clinical Pharmacy|August 20, 2015
Adverse drug reactions experience in a teaching hospital in JordanMohammed Alsbou, Sameh Alzubiedi, Hamed Alzobi, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|June 7, 2018
A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infectionMohammad I Saleh, Nagham N HindiClinical and Experimental Pharmacology & Physiology|March 26, 2018
Patient characteristics associated with peglyated interferon alfa-2a induced neutropenia in chronic hepatitis C patientsNagham N Hindi, Mohammad I SalehPageof 2